{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:26:57Z","timestamp":1788607617840,"version":"build-2803163510"},"reference-count":59,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["950-231335"],"award-info":[{"award-number":["950-231335"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["23545"],"award-info":[{"award-number":["23545"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cellular Signaling and Cancer Metastasis"},{"name":"CIHR Foundation","award":["148363"],"award-info":[{"award-number":["148363"]}]},{"DOI":"10.13039\/100015751","name":"Qu\u00e9bec Consortium for Drug Discovery","doi-asserted-by":"publisher","award":["SYN-366"],"award-info":[{"award-number":["SYN-366"]}],"id":[{"id":"10.13039\/100015751","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Bordeaux, INSERM","award":["Universit\u00e9 de Montr\u00e9al"],"award-info":[{"award-number":["Universit\u00e9 de Montr\u00e9al"]}]},{"name":"CIHR Operating","award":["191678"],"award-info":[{"award-number":["191678"]}]},{"name":"Cell therapy acceleration","award":["Universit\u00e9 de Montr\u00e9al"],"award-info":[{"award-number":["Universit\u00e9 de Montr\u00e9al"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy approaches based on T cells provided breakthroughs in cancer treatment but could cause many immune-related adverse events, and their efficacy is limited for many cancers with an acquired dysfunction\/exhaustion of T cells. The present study presents a novel role in immunity for proprotein convertase subtilisin-kexin 7 (PCSK7), the seventh proprotein convertase of the 9-membered secretory proprotein convertase subtilisin-kexin (PCSK)-family.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed cell surface levels of various immune checkpoint proteins in human and mouse cell models in the presence or absence of PCSK7 expression. Injection of mouse colon carcinoma MC38 cells in the spleen of mice lacking either\n                      <jats:italic>Pcsk7<\/jats:italic>\n                      ,\n                      <jats:italic>Pcsk9<\/jats:italic>\n                      or both (double knockout) allowed the analysis of the extent of hepatic tumor metastasis. We also estimated the cell surface expression of checkpoint proteins in CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells from healthy human subjects in which\n                      <jats:italic>PCSK7<\/jats:italic>\n                      expression was silenced by CRISPR Cas9 gRNA knockdown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Bioinformatic and cellular studies showed enrichment of PCSK7 mRNA levels in CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, which correlates with those of immune checkpoint proteins (ICPs; eg,\n                      <jats:italic>LAG3<\/jats:italic>\n                      ,\n                      <jats:italic>CTLA4<\/jats:italic>\n                      ,\n                      <jats:italic>PD1<\/jats:italic>\n                      and\n                      <jats:italic>TIGIT<\/jats:italic>\n                      ) responsible for T-cell dysfunction. Indeed, cells lacking PCSK7 and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells derived from\n                      <jats:italic>Pcsk7<\/jats:italic>\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice exhibited \u226540% lower cell-surface levels of ICPs. Similarly, CRISPR-Cas9 editing of\n                      <jats:italic>PCSK7<\/jats:italic>\n                      (\n                      <jats:italic>PCSK7<\/jats:italic>\n                      i) in primary human T cells resulted in lower expression of ICPs and a reduced proportion of cells expressing multiple ICPs, without altering the expression of activation markers. Moreover, proprotein convertase subtilisin-kexin 9 (PCSK9), the ninth PCSK family member, enhances the degradation of the low-density lipoprotein-receptor and major histocompatibility complex-I proteins. Indeed,\n                      <jats:italic>Pcsk9<\/jats:italic>\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice were previously reported to exhibit reduced liver tumor metastasis. In the present studies, we report synergistic and complementary functions of PCSK7 and PCSK9, as the loss of each one of the convertases reduced by twofold the number of liver metastases, but the strongest reduction (&gt;90%) was observed in double KO (\n                      <jats:italic>Pcsk7<\/jats:italic>\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      ,\n                      <jats:italic>Pcsk9<\/jats:italic>\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      ) mice. In\n                      <jats:italic>Pcsk7<\/jats:italic>\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mouse tumors the antitumorigenic activity of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells was enhanced and the levels of ICPs were reduced.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Cumulatively, our data provide a\n                      <jats:italic>PCSK7<\/jats:italic>\n                      i strategy to reduce the levels of cell-surface ICPs, thereby rationalizing the use of\n                      <jats:italic>PCSK7<\/jats:italic>\n                      i in T-cell immunotherapies alone or in combination with a PCSK9 inhibitor\/silencer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-011364","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T19:25:22Z","timestamp":1750015522000},"page":"e011364","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Blockade of colon cancer metastasis via single and double silencing of\n                    <i>PCSK7<\/i>\n                    \/\n                    <i>PCSK9<\/i>\n                    : enhanced T cells cytotoxicity in mouse and human"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8342-3484","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Porcheron","sequence":"first","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"},{"name":"Inserm, UMR1312, BRIC, Bordeaux Institute of Oncology, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9630-5831","authenticated-orcid":false,"given":"Mailys","family":"Le Devehat","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5475-8006","authenticated-orcid":false,"given":"Anna","family":"Roubtsova","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4069-3529","authenticated-orcid":false,"given":"Hadi","family":"Bayat","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2331-591X","authenticated-orcid":false,"given":"Alexandra","family":"Evagelidis","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jafarzadeh","sequence":"additional","affiliation":[{"name":"Maisonneuve-Rosemont Hospital Research Center, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2283-7632","authenticated-orcid":false,"given":"Vatsal","family":"Sachan","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-1542","authenticated-orcid":false,"given":"Nathalie","family":"Labrecque","sequence":"additional","affiliation":[{"name":"Institut de recherches cliniques de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7208-1278","authenticated-orcid":false,"given":"Alexie","family":"Fonta Holder","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-090X","authenticated-orcid":false,"given":"Delia","family":"Susan-Resiga","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7558-997X","authenticated-orcid":false,"given":"Rachid","family":"Essalmani","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Boudreau","sequence":"additional","affiliation":[{"name":"Maisonneuve-Rosemont Hospital Research Center, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-5277","authenticated-orcid":false,"given":"Annik","family":"Prat","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0693-5585","authenticated-orcid":false,"given":"Rebecca","family":"Cusseddu","sequence":"additional","affiliation":[{"name":"Institut de recherches cliniques de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-2642","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[{"name":"Institut de recherches cliniques de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-0384","authenticated-orcid":false,"given":"Abdel-Majid","family":"Khatib","sequence":"additional","affiliation":[{"name":"Inserm, UMR1312, BRIC, Bordeaux Institute of Oncology, University of Bordeaux, Bordeaux, France"},{"name":"Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-7287","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[{"name":"Maisonneuve-Rosemont Hospital Research Center, Montreal, Quebec, Canada"},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-9342","authenticated-orcid":false,"given":"Nabil G","family":"Seidah","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal Biochemical Neuroendocrinology Research Unit, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"2026052722353712000_13.6.e011364.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3699"},{"key":"2026052722353712000_13.6.e011364.2","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab035"},{"key":"2026052722353712000_13.6.e011364.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.8.3388"},{"key":"2026052722353712000_13.6.e011364.4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/endrev\/bnae031","article-title":"The Biology and Clinical Implications of PCSK7","volume":"46","author":"Sachan","year":"2025","journal-title":"Endocr Rev"},{"key":"2026052722353712000_13.6.e011364.5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.192344"},{"key":"2026052722353712000_13.6.e011364.6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.011775"},{"key":"2026052722353712000_13.6.e011364.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26297"},{"key":"2026052722353712000_13.6.e011364.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-02893-0","article-title":"Shedding of cancer susceptibility candidate 4 by the convertases PC7\/furin unravels a novel secretory protein implicated in cancer progression","volume":"11","author":"Duval","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026052722353712000_13.6.e011364.9","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1111\/febs.15212","article-title":"Proprotein convertase 7 (PCSK7) reduces apoA-V levels","volume":"287","author":"Ashraf","year":"2020","journal-title":"FEBS J"},{"key":"2026052722353712000_13.6.e011364.10","doi-asserted-by":"crossref","first-page":"155736","DOI":"10.1016\/j.metabol.2023.155736","article-title":"PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease","volume":"150","author":"Sachan","year":"2024","journal-title":"Metab Clin Exp"},{"key":"2026052722353712000_13.6.e011364.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100130","article-title":"The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer","volume":"62","author":"Seidah","year":"2021","journal-title":"J Lipid Res"},{"key":"2026052722353712000_13.6.e011364.12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature New Biol"},{"key":"2026052722353712000_13.6.e011364.13","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-021-00821-2"},{"key":"2026052722353712000_13.6.e011364.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-12148-2","article-title":"Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"2026052722353712000_13.6.e011364.15","doi-asserted-by":"crossref","first-page":"947756","DOI":"10.3389\/fimmu.2022.947756","article-title":"Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2026052722353712000_13.6.e011364.16","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026052722353712000_13.6.e011364.17","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820917527","article-title":"Advances in immunotherapy for colorectal cancer: a review","volume":"13","author":"Golshani","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"2026052722353712000_13.6.e011364.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"key":"2026052722353712000_13.6.e011364.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.005"},{"key":"2026052722353712000_13.6.e011364.20","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1210-1248"},{"key":"2026052722353712000_13.6.e011364.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0086"},{"key":"2026052722353712000_13.6.e011364.22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.988561","article-title":"Therapeutic potential of the Proprotein Convertase Subtilisin\/Kexin family in vascular disease","volume":"13","author":"Suur","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026052722353712000_13.6.e011364.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.022"},{"key":"2026052722353712000_13.6.e011364.24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407"},{"key":"2026052722353712000_13.6.e011364.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.04.021"},{"key":"2026052722353712000_13.6.e011364.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314698110"},{"key":"2026052722353712000_13.6.e011364.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22354"},{"key":"2026052722353712000_13.6.e011364.28","doi-asserted-by":"publisher","DOI":"10.1593\/neo.121252"},{"key":"2026052722353712000_13.6.e011364.29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041717"},{"key":"2026052722353712000_13.6.e011364.30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M807322200"},{"key":"2026052722353712000_13.6.e011364.31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1189\/jlb.70.1.18","article-title":"Unlocking the secrets of cytotoxic granule proteins","volume":"70","author":"Smyth","year":"2001","journal-title":"J Leukoc Biol"},{"key":"2026052722353712000_13.6.e011364.32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-022-02584-y","article-title":"PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity","volume":"42","author":"Gu","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"2026052722353712000_13.6.e011364.33","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.18632\/oncotarget.26725","article-title":"AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer","volume":"10","author":"Goyette","year":"2019","journal-title":"Oncotarget"},{"key":"2026052722353712000_13.6.e011364.34","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.7150\/ijbs.93668","article-title":"Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy","volume":"20","author":"Xu","year":"2024","journal-title":"Int J Biol Sci"},{"key":"2026052722353712000_13.6.e011364.35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.2.303"},{"key":"2026052722353712000_13.6.e011364.36","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202312141","article-title":"Rapid turnover of CTLA4 is associated with a complex architecture of reversible ubiquitylation","volume":"224","author":"Tey","year":"2025","journal-title":"J Cell Biol"},{"key":"2026052722353712000_13.6.e011364.37","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/1608582","article-title":"Exosomal PDL1 Suppresses the Anticancer Activity of CD8+ T Cells in Hepatocellular Carcinoma","volume":"2024","author":"Hu","year":"2024","journal-title":"Anal Cell Pathol (Amst)"},{"key":"2026052722353712000_13.6.e011364.38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.506220"},{"key":"2026052722353712000_13.6.e011364.39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601520"},{"key":"2026052722353712000_13.6.e011364.40","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjz008"},{"key":"2026052722353712000_13.6.e011364.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201524598"},{"key":"2026052722353712000_13.6.e011364.42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006758200"},{"key":"2026052722353712000_13.6.e011364.43","first-page":"4003","article-title":"Selective implantation and growth in rats and mice of experimental liver metastasis in acinar zone one","volume":"49","author":"Barber\u00e1-Guillem","year":"1989","journal-title":"Cancer Res"},{"key":"2026052722353712000_13.6.e011364.44","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq2630","article-title":"Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer","volume":"7","author":"Kwon","year":"2022","journal-title":"Sci Immunol"},{"key":"2026052722353712000_13.6.e011364.45","doi-asserted-by":"publisher","DOI":"10.1097\/Shk.0000000000000682"},{"key":"2026052722353712000_13.6.e011364.46","doi-asserted-by":"crossref","first-page":"112898","DOI":"10.1016\/j.intimp.2024.112898","article-title":"MRG15 aggravates sepsis-related liver injury by promoting PCSK9 synthesis and secretion","volume":"140","author":"Gu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026052722353712000_13.6.e011364.47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2008111","article-title":"Improving cancer immunotherapy by targeting IL-1","volume":"10","author":"Xiao","year":"2021","journal-title":"Oncoimmunology"},{"key":"2026052722353712000_13.6.e011364.48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.5483\/BMBRep.2024-0162","article-title":"Targeting proprotein convertase subtilisin\/kexin type 7 in macrophages as a therapeutic strategy to mitigate myocardial infarction-induced inflammation","volume":"57","author":"Moon","year":"2024","journal-title":"BMB Rep"},{"key":"2026052722353712000_13.6.e011364.49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.320056"},{"key":"2026052722353712000_13.6.e011364.50","doi-asserted-by":"crossref","unstructured":"Moon SH , Ki HW , Yoon NH , et al . PCSK9 inhibition in myeloid cells enhances cardioprotection beyond its ldl cholesterol-lowering effects. medRxiv [Preprint] 2024. doi:10.1101\/2024.08.27.24312680","DOI":"10.1101\/2024.08.27.24312680"},{"key":"2026052722353712000_13.6.e011364.51","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1080\/14796694.2024.2421151","article-title":"Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer","volume":"20","author":"Wang","year":"2024","journal-title":"Future Oncol"},{"key":"2026052722353712000_13.6.e011364.52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2019.12.027","article-title":"Proprotein convertases: Key players in inflammation-related malignancies and metastasis","volume":"473","author":"Siegfried","year":"2020","journal-title":"Cancer Lett"},{"key":"2026052722353712000_13.6.e011364.53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.8.5433"},{"key":"2026052722353712000_13.6.e011364.54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200166"},{"key":"2026052722353712000_13.6.e011364.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.04.002"},{"key":"2026052722353712000_13.6.e011364.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00312-2"},{"key":"2026052722353712000_13.6.e011364.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035"},{"key":"2026052722353712000_13.6.e011364.58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/CCO.0000000000001014","article-title":"Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence","volume":"36","author":"Benhima","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"2026052722353712000_13.6.e011364.59","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075859","article-title":"Cardiovascular toxicity of immune therapies for cancer","volume":"385","author":"Palaskas","year":"2024","journal-title":"BMJ"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:35:45Z","timestamp":1779946545000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,15]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/jitc-2024-011364"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011364","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}